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The bis-azo compound FP-21399 inhibits HIV-1 infection. We now show that FP-21399 acts on the HIV-1 envelope
glycoprotein to prevent viral replication. This compound targets the entry step of the HIV-1 replication cycle as demonstrated
by time-of-addition and single cycle viral entry assays. The entry of SIVmac239, which uses the same coreceptors (CD4/CCR5)
as HIV-1, was not inhibited by FP-21399, indicating that the antiviral effect of FP-21399 is specific for the HIV-1 envelope
glycoprotein and is not dependent upon the cellular receptors CD4 and CCR5. FP-21399 inhibits neither the activity of HIV-1
reverse transcriptase nor the expression of HIV-1 early mRNA. Finally, this compound inhibits gp120 shedding of the T-tropic
virus. Our results suggest that the anti-HIV activity of FP-21399 is due to its interaction with HIV-1 gp120/41 complex during
viral entry. © 1998 Academic Press
INTRODUCTION
The HIV-1 envelope glycoproteins gp120 and gp41
play an important role in viral entry and syncytium for-
mation, and the V3 loop of gp120 plays a key part in this
membrane fusion process (De Jong et al., 1992; Page et
al., 1992; Shioda et al., 1992). HIV-1 envelope glycopro-
tein-mediated membrane fusion can be observed at the
viral entry level (viral–cell membrane fusion) as well as
after HIV-1 replication in the infected cell (cell–cell fu-
sion) (Lifson et al., 1986; Sodroski et al., 1986). In the
former case, gp120-mediated membrane fusion leads to
a process of fusion uncoating which allows the HIV-1
core to enter the cell. In the latter case, gp120-mediated
membrane fusion induces the formation of multinucle-
ated cells or syncytia. Whether gp120-mediated cell
membrane fusion at the entry level is the same as gp120-
mediated syncytium formation among CD41 cells re-
mains unclear (Camerini et al., 1990; Celada et al., 1990;
Lifson et al., 1991). Although the recent identification of
HIV-1 coreceptors has suggested that both M- and T-
tropic viruses enter host cells by gp120/41 fusion with the
cell membrane, only T-tropic viruses cause syncytium
formation in T cell lines (Fouchier et al., 1992; Shioda et
al., 1992; Westervelt et al., 1992).
Compounds that inhibit gp120/41-mediated cell mem-
brane fusion can target either a viral protein (like gp120
or gp41) or a cellular component (like CD4 or a corecep-
tor in viral entry). It is important to differentiate between
these two possibilities, particularly for novel compounds
whose mechanisms of actions have not yet been fully
elucidated. CD4 blockers are examples of compounds
that target the cellular receptor. CD4 blockers inhibit
syncytium formation and gp120-CD4 binding (Cardin et
al., 1991; Reed et al., 1994; Stein et al., 1991). On the other
hand, reverse transcriptase inhibitors and protease in-
hibitors, which block gp120-mediated syncytium forma-
tion indirectly by inhibiting viral replication, target viral
factors. Few compounds have been reported to inhibit
gp120-mediated membrane fusion by specifically inter-
acting with the viral protein at the entry level.
The bis-azo compound FP-21399 (FP) (Fig. 1) inhibits
HIV envelope protein-mediated membrane fusion and
weakly inhibits binding of CD4 and gp120. The V3 loop
appears to be important to the action of this compound
(Ono et al., 1997). Herein we examined the potential
target of this compound in single cycle viral replication
assays and determined the anti-HIV specificity of this
compound with recombinant virus infection of canine
thymocytes expressing HIV-1 coreceptors. A recombi-
nant SIV was also tested in this assay system, and the
entry of this virus was not inhibited by FP although SIV
and HIV use the same receptors for entry. The HIV-1
gp120 shedding assay and immunofluorescent assay are
employed to examine the interaction of this compound
with HIV-1 envelope glycoproteins. Our study establishes
that the target of FP-21399 is the HIV-1 envelope glyco-
protein, the antiviral effect is specific for HIV-1, and the
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function of this compound depends upon the structural
features of viral gp120/41.
RESULTS
FP-21399 affects HIV-1 replication at a
postattachment stage
To investigate the potential stage at which FP acts
during the HIV-1 replication cycle, time-of-addition exper-
iments were performed. These studies focus on four
stages of the HIV replication cycle: viral attachment,
postattachment (penetration and provirus formation), ex-
pression of early mRNA and genomic RNA, and the later
stage of viral replication. The time points of drug addition
are designed according to the published studies (Lu et
al., 1992; Perelson et al., 1996; Srivastava et al., 1991; Wei
et al., 1995). The lowest production of the surrogate
marker (p24 in this case) at a time point indicates the
stage in the viral replication cycle which is targeted by
the drug.
FP was added to PBMC that were acutely infected with
HIV-1 at different time points. Unbound virus was
washed off at 2 h postinfection; FP was present in the
culture for 2 h under each condition. FP strongly inhibited
HIV-1 replication as measured by p24 expression when
this compound was applied at 30 min and 1 h postinfec-
tion. In contrast, little inhibition was noted when FP was
applied at other time points (Fig. 2). It is noteworthy that
the maximal decrease of p24 production was not ob-
served when the drug was applied to the cells at the
same time as virus (0 min postinfection). These results
suggest that FP does not compete for initial virus attach-
ment to cells (Fig. 2). The kinetics of p24 production after
FP treatment suggest that this compound affects HIV-1
replication at a postadsorption step.
To confirm that the maximum decrease of p24 produc-
tion at 30 min and 1 h postinfection was the result of FP
acting at this stage of viral replication, a different set of
time-of-addition experiments was performed. The levels
of p24 antigen of FP-treated cells versus mock-treated
control at each individual time point were compared. FP
was present in each culture for 34 h to maximize FP’s
effect on the infected cell. P24 was measured at 64 h
postinfection. Maximal inhibition of p24 production was
observed when FP was added at 30 min and 1 h postin-
fection (Fig. 3). No inhibition of p24 production was
observed if the FP was added at time points $2 h. Taken
together, the results of time-of-addition experiments in-
FIG. 1. The structure of FP-21399.
FIG. 2. The p24 expression at different time points after FP treatment.
Each bar represents the p24 level from HIV-1IIIB infected PBMC after FP
treatment. The times expressed in minutes represent the different
points at which FP was applied to the cultures postinfection. The last
bar represents p24 production without FP treatment at the end point
(postinfection 3660 min).
FIG. 3. The p24 expression at different time points compared with the
mock-treated control. FP was applied to the HIV-1IIIB-infected PBMC at
30, 60, 120, and 360 min postinfection. FP was present in the culture for
34 h under each assay condition. p24 level compared with the control
in each FP-treated condition (h).
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dicate that FP affects a postattachment stage of the
HIV-1 replication cycle, presumably at the entry level.
Drug-resistant viruses have been very useful in distin-
guishing between compounds that target virion compo-
nents from ones that target cellular molecules. A drug-
resistant virus should show decreased sensitivity to the
given compound at its targeted stage or on its targeted viral
protein. We employed an HIV-1 virus which has a reduced
sensitivity to FP (Ono et al., 1997) to study the effect of FP on
the postattachment stage (30 min and 1 h postinfection).
The FP-resistant HIV-1 was selected after having been
exposed to increasing concentrations of FP in culture (Ono
et al., 1997). The production of p24 antigen was greatly
decreased after FP treatment of the wild type HIV-1 at 30
min and 1 h postinfection (Fig. 4a). The FP-resistant HIV-1,
however, was not inhibited by this compound at any of
these time points. FP-resistant HIV-1 showed a decreased
sensitivity at the postattachment stage. This result further
substantiates our earlier observation that FP targets the
entry stage of the HIV-1 life cycle.
If FP blocks viral replication at a postattachment step,
the inhibition of viral replication can also be detected
with other viral markers rather than p24. Therefore, we
studied the action of FP on HIV-1 LTR expression, a
surrogate marker for the formation of HIV-1 provirus. FP
was added to the culture at 0, 30, 60, and 120 min
postinfection. FP treatment at 30 min and 1 h postinfec-
tion greatly inhibited HIV-1 provirus production of wild-
type HIV, but not that of FP-resistant HIV (Fig. 4b). In
addition, FP did not inhibit wild-type HIV-1 reverse tran-
scriptase (RT) activity at drug concentrations from 1 to 20
mM in in vitro RT assay (data not shown), which indicates
that FP does not target HIV-1 RT. The decreased HIV-1
LTR production is thereby a result of FP inhibiting viral
infection at the entry level.
FP-21399 does not inhibit HIV-1 attachment to cells
To clarify that the anti-HIV effect of FP is due to this
compound interfering with the fusion process rather than
the adsorption step, we examined the activity of FP on
HIV-1IIIB attachment. A TCID50 of 100 of HIV-1IIIB was
used to acutely infect six million PBMC. FP was added to
cells together with virus. Both FP and unbound viruses
were washed off after incubation with cells for 30, 60,
120, and 300 min. The cell-attached viruses were de-
tected with the p24 antigen assay and represented as
the real p24 titer in the cell lysate from each incubation
period (Fig. 5a). It is noteworthy that the p24 detected in
each incubation time point is a sum of the p24 in the
virion which attached on the cell surface and which
penetrated into the cell. The detected p24 represents the
amount of cell-associated virion, since de novo synthesis
of Gag protein does not occur in the range of postinfec-
tion times from 0 to 5 h. This assay showed that FP does
not inhibit HIV-1IIIB attachment to the cell, as in each
tested point a similar amount of cellular associated p24
is detected in both FP treated and mock-treated cells.
The result also confirms the previous finding that .90%
of viruses are adsorbed to the host cells within postin-
fection 2 h (Hollinger et al., 1994; Lu et al., 1992; Srivas-
tava et al., 1991).
In studying FP we have observed that this compound
is easily dissolved in water and that the anti-HIV activity
FIG. 4. FP inhibits HIV-1 replication in the postattachment stage. (a) FP inhibited HIV-1 p24 expression when FP was added at 30 and 60 min
postinfection. The p24 expression of an HIV-1 mutant was not inhibited. p24 level of HIV-1IIIB (3) and HIV-1 mutant (0) compared with mock-treated
control. (b) FP inhibited HIV-1IIIB LTR expression when FP was added at the postattachment stage. The LTR expression of the HIV-1 mutant was not
inhibited. Lanes 1 and 10, w 3 174 FR DNA/HaeIII fragments; lanes 2–5, HIV-1IIIB LTR detected from the culture after FP was applied at 0, 30, 60, and
120 min postinfection; lanes 6–9, HIV-1 mutant LTR detected from the culture after FP was applied at 0, 30, 60, and 120 min postinfection. (c) b-Globin
DNA detected from the above samples.
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depends upon this drug constantly being present in the
culture medium. Removing this compound by washing
the cells with PBS after the addition of FP together with
virus to cells for 2 h causes FP to lose more than 60% of
its anti-HIV activity as shown (Fig. 5b). If FP is added
back to the infected cells after the wash procedure, FP
totally blocks the viral replication. Taken together, these
results (Figs. 5a and 5b) indicate that FP may block viral
entry by retention of virion on the cell surface. To exam-
ine this hypothesis, we employed an immunofluorescent
assay testing the effect of FP on virion gp120 which
attached to the cell surface.
FP-21399-mediated retention of gp120 on the PBMC
surface
To examine the effect of FP on HIV-1 envelope glyco-
protein, an immunofluorescent assay employing mono-
clonal antibody against gp120 was performed to show
the effect of FP on HIV-1 gp120 in HIV-1 virion infection of
the natural target cells. At 40 min postinfection, HIV-1IIIB
acutely infected PBMC without drug treatment showed
strong staining with the mAb against gp120. Similar
staining was observed on the cells treated with either
AZT or FP (Figs. 6a, 6c, and 6e). At 2 h postinfection (the
second staining point), gp120 staining was no longer
observed in HIV-1IIIB-infected PBMC treated with AZT or
without drug (Figs 6f and 6b). The infected PBMC treated
with FP, however, showed persistent strong gp120-spe-
cific fluorescent staining at 2 h postinfection (Fig. 6d).
These results indicate that FP interferes with gp120 turn-
over on the cell surface, presumably by stabilizing the
noncovalent connection of gp120 and gp41 in the enve-
lope of HIV-1IIIB, a T-tropic virus.
FP-21399 inhibits CCR5- and CXCR4-facilitated infection
by M-tropic or T-tropic HIV-1 at the entry level
The ability of FP to inhibit entry of HIV-1 was examined by
a viral entry assay using recombinant viruses that are able
to replicate for a single cycle only. Canine thymocytes
(Cf2Th) were used in this assay enabling us to focus on
selectively transfected cellular receptors. Since only trans-
fected human cell receptors are present, this assay ex-
cludes other cellular components on the human cell sur-
face which may play a minor role in the activity of FP.
Expressor plasmids of human CD4, CXCR4 (T-tropic virus
coreceptor), or CCR5 (M-tropic virus coreceptor) were
transfected into Cf2Th cells. Recombinant viruses (Choe et
al., 1996) that express the envelope glycoproteins of HIV-1
M-tropic (YU-2) and T-tropic (HXBc2) strains and those of
amphotropic murine leukemia virus (A-MuLV) were utilized
in this study. These recombinant viruses differ only in their
envelope proteins. The efficiency of viral entry was mea-
sured by CAT activity in Cf2Th cells following infection
(Choe et al., 1996).
FP inhibited M-tropic as well as T-tropic HIV-1 infections
in cells expressing CCR5 or CXCR4, respectively, in a dose-
dependent manner (Fig. 7). FP did not inhibit the infection of
viruses with the A-MuLV envelope glycoproteins in these
cells, indicating that the antiviral activity of FP is specific for
HIV-1 envelope glycoproteins. Since the genes directing the
replication activities after entry in these recombinant vi-
FIG. 5. FP does not block HIV-1IIIB attaching to PBMC. (a) The p24 of
cell lysate was detected after incubating virus with cells for different
time periods. (1) p24 of cell lysate from FP-treated cells. (h) p24 of cell
lysate from FP mock-treated cells. (b) The anti-HIV effect of FP requires
that this compound be constantly present in the culture medium. The
antigen p24 was detected after culturing cells for 7 days. (n) Percent-
age of p24 in the supernatant of culture to which 5 mM of FP was added
with virus together and washed off after 2 h. ({) Percentage of p24 in
the supernatant of culture to which 5 mM of FP was added with virus
together for 2 h and added again after the wash. (E) Percentage of p24
(172.3 ng/ml 5 100%) from the supernatant of culture that was mock
treated with FP.
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ruses are identical, this study indicates that FP inhibits
replication at the entry step of both T- and M-tropic viruses.
The results also suggests that FP interferes with the ability
of the HIV-1 envelope glycoproteins to use either CD4-
CXCR4 or CCR5 as a coreceptor. This inhibition was com-
plete at lower drug concentrations for cells containing CD4-
CXCR4 (for entry of T-tropic virus) than those with CD4-
CCR5 (for entry of M-tropic virus) (Fig. 7).
FP does not inhibit CD4/CCR5- or CD4/gpr15-
facilitated SIV entry
Like HIV-1, the entry of SIV requires CD4 and a core-
ceptor such as CCR5 on the host cell surface. Two
orphan seven-transmembrane segment receptors, gpr1
and gpr15, have been recently identified as coreceptors
for SIV (Farzan et al., 1997). We have employed Cf2Th
cells transfected with human CD4/CCR5 or CD4/gpr15 to
examine whether the action of FP is selective for HIV-1
gp120/41 or for any envelope glycoprotein which uses
the same cellular receptors for viral entry.
FP specifically inhibited HIV-1 but not SIVmac239 from
entering the cells (Fig. 8), whether CD4/CCR5 or CD4/
gpr15 was used for SIV infections. The observation that
the entry of SIVmac239, which uses the same coreceptors
(CD4/CCR5) as HIV-1, was not inhibited by FP provides
strong evidence that the antiviral effect of FP is specific
for the HIV-1 envelope glycoprotein and is not dependent
upon the cellular receptors CD4 and CCR5.
In an assay exploring the ability of FP to inhibit SIV-
mac239 and SIVmac251 infections of human PBMCs by
measuring production of SIV p27 Gag protein, both vi-
ruses showed no inhibition by FP at concentrations of
0.08 to 8 mM. In a parallel assay, HIV-1 infections of
human PBMCs are inhibited by FP at an ID50 of 0.8 mM
(Table 1a). These data show that FP does not inhibit
infections with SIVmac239 and SIVmac251, which is con-
sistent with the results in Fig. 5 showing that SIV entry is
not prevented by FP on Cf2Th cells transfected with
human CD4/CCR5 or CD4/gpr15.
FP-21399 does not inhibit HIV-1 early mRNA
expression
To determine whether FP acts at another early stage
of viral replication, we examined HIV-1-spliced mRNA
FIG. 6. FP prolongs gp120 staining on the surface of PBMC. Texas red staining of HIV-1IIIB infected PBMC: (a) postinfection 40 min; (b) postinfection
120 min; (c) treated with 2 mM FP until postinfection 40 min; (d) treated with 2 mM FP until postinfection 120 min; (e) treated with 2 mM AZT until
postinfection 40 min; (f) treated with 2 mM AZT until postinfection 120 min.
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FIG. 6—Continued
expression after FP treatment. The drug was present in
the cultures until the cells were harvested (68 h postin-
fection). FP did not inhibit tat, rev, and env mRNA expres-
sion, when the compound was added to cultures at 2 h
postinfection (Figs. 9a–9d). Under the identical assay
conditions, AZT was able to decrease the same mRNA
expression in a dose-dependent manner secondary to
inhibiting RT activity. Since FP does not inhibit HIV-1
LTR-directed early mRNA expression, these results show
that FP does not inhibit the early events in the viral
replication cycle immediately following HIV-1 DNA inte-
gration.
FP-21399 inhibits T-tropic virus gp120 shedding
Previous reports have shown that cell surface ex-
pressed gp120 can be dissociated (shedding) from gp41
into the culture supernatant (Hart et al., 1991; Moore et
al., 1990; Thali et al., 1992). This dissociation is increased
when sCD4 is added into the culture medium. It has
been suggested that gp120 shedding may be related to
the conformational change which occurs in the process
of HIV-1-mediated cell membrane fusion. However, the
exact relationship between gp120 shedding and confor-
mational changes related to HIV-1 entry has not been
fully elucidated (Binley et al., 1997; Hart et al., 1991;
Moore et al., 1990; Sattentau et al., 1991; Thali et al.,
1992).
The plasmids expressing ADA (M-tropic) or HXBc2
(T-tropic) envelope glycoproteins were used to study the
effect of FP on both natural and sCD4-induced gp120
shedding. FP inhibited both natural and sCD4-induced
gp120 shedding of T-tropic envelope glycoprotein in a
dose-dependent manner. Neither natural nor sCD4-in-
duced shedding of gp120 from M-tropic virus ADA, how-
ever, was inhibited (Figs. 10a and 10c). Similar amounts
of gp120 and gp160 were expressed in the cell lysates of
these samples (Figs. 10b and 10d). The results showed
that, in the context of gp120 shedding, a dose-dependent
inhibition of gp120 shedding by FP occurred from T-tropic
virus only; gp120 shedding by the M-tropic virus ADA
was not inhibited and actually increased in the presence
of FP. When the infectious viruses of strain ADA and
HXBc2 were employed in an antiviral susceptibility assay
in PBMC culture, a similar ID50 concentration was ob-
served to inhibit replication of both viruses (Table 1a).
The results of the gp120 shedding assay, therefore, sug-
gest that the effect of FP in inhibiting gp120 shedding
depends on the structural difference in the HIV-1 enve-
lope glycoprotein of T- and M-tropic viruses.
DISCUSSION
The bis-azo compound FP-21399 was reported previ-
ously to inhibit HIV-1 envelope glycoprotein-mediated
membrane fusion. In that study FP-21399 was shown to
TABLE 1a
The Inhibition of HIV-1 and SIV Infection by FP
Virus ID50 (mM)
HIV-1IIIB (HXBc2) 0.8
HIV-1 ADA 0.8
SIVmac239 . 8.0
SIVmac251 . 8.0
Note. 106 human PBMC were acutely infected with 2000 TCID50 of
virus. FP was added immediately after the acute infection and was
present in the culture for 7 days. ID50 was calculated by the median-
effect equation (Chou et al., 1984) with Systat Version 5.1 software.
FIG. 7. FP inhibits M-tropic (YU2) and T-tropic (HXBc2) HIV-1 entry in
Cf2Th cells. The CAT activity in the presence of increasing amount of
FP in each culture is represented by the columns and expressed as
percentage of conversion. CAT activity in Cf2Th cells infected with YU2
(3), HXBc2 (n), and amphotropic MuLV ( ).
FIG. 8. FP does not inhibit CD4/CCR5- or CD4/gpr15-facilitated SIV
entry. CAT activity in Cf2Th cells transfected with CD4/gpr15 and
infected with SIV (u), transfected with CD4/CCR5 and infected with SIV
(n), and transfected with CD4/CCR5 and infected with YU2 (3).
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inhibit the fusion of CD41 cells with cells that express
gp160 (Ono et al., 1997). In the present study, we have
shown that FP inhibits viral entry by acting specifically on
the HIV-1 envelope glycoprotein rather than on cellular
receptors. The antifusion effect of FP is possibly due to
the ability of this compound to interfere with the HIV-1
gp120/41 conformational change in the envelope-medi-
ated membrane fusion process during viral entry.
FP acts on the viral entry stage rather than at other
stages of the HIV-1 replication cycle as demonstrated in
both the time-of-addition and the single cycle viral repli-
cation assays. To exclude other targets in the early stage
of the HIV-1 life cycle, the effects of FP on HIV-1 RT and
HIV-1 early mRNA expression were studied. Results
showed that FP inhibited neither the activity of HIV-1 RT
nor the expression of HIV-1 early mRNA. Table 1b sum-
marizes the experimental results in the study of the
potential target of FP in the viral replication cycle.
FP effectively inhibits HIV-1 but not SIV infections,
although the latter shares the same viral entry receptors
as HIV-1. This shows that the action of FP is specific for
the HIV-1 envelope glycoprotein and not a related viral
envelope glycoprotein using the same cellular receptors
for viral entry. This result indicates that FP acts specifi-
cally on HIV-1 gp120 and not on cellular receptor CD4
and CCR5.
The fact that FP inhibited gp120 shedding of T-tropic
virus is consistent with the immunofluorescent observa-
tion with HIV-1IIIB (T-tropic virus) showing that gp120 is
FIG. 9. FP does not inhibit HIV-1 early mRNA expression when FP
was added at 2 h postinfection. (a to c) tat, rev, and env DNA, respec-
tively. Lanes 1 and 12, w 3 174 FR DNA/HaeIII fragments; lanes 2–6,
HIV-1 DNA detected from HIV-1IIIB-infected PBMC treated with 4, 1, 0.25,
0.063, and 0 mM FP, respectively; lanes 7–11, HIV-1 DNA detected from
HIV-1IIIB-infected PBMC treated with 4, 1, 0.25, 0.063, and 0 mM AZT,
respectively. (d) b-globin DNA from the above samples.
FIG. 10. FP inhibits T-tropic virus gp120 shedding. Virus envelope
glycoproteins were expressed in Cos-1 cells in the presence or ab-
sence of FP. The released protein from cells incubated without or with
20 mg/ml sCD4 and cell lysates were immunoprecipitated with HIV-
positive serum. (a) gp120 shedding from cells transfected with HXBc2
env expressor and treated with and without FP. (b) The gp120 and
gp160 in cell lysate from the samples in a. (c) gp120 shedding from
cells transfected with ADA env expressor and treated with and without
FP. (d) The gp120 and gp160 in cell lysate from the samples in c.
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retained on the cell surface in the presence of FP. The
conformational changes in gp120 upon CD4 binding are
sufficient to cause the gp120 to physically dissociate or
shed from the viral surface in the laboratory-adapted
isolates of HIV-1 (Berger et al., 1991; Hart et al., 1991;
Sattentau et al., 1991; Thali et al., 1992). The disruption of
the noncovalent association between gp120 and gp41
causes gp120 shedding and leaves the membrane-an-
chored gp41 subunit behind. The fusion-entry process is
presumably triggered by the conformational changes be-
tween gp120 and gp41 (Binley et al., 1997; Chan et al.,
1997; Weissenhorn et al., 1996, 1997). Although gp120
shedding is not necessarily an integral step of the mem-
brane fusion event, gp120 shedding may be a useful
marker of the conformational change. Also, compounds
such as NB-DNJ, which cause conformational changes
of gp120, inhibit gp120 shedding (Fischer et al., 1996).
The result of gp120 shedding in our study suggests
that the anti-HIV activity of FP may be involved in stabi-
lizing the noncovalent association between gp120 and
gp41 in the T-tropic virus. FP appears only to inhibit
gp120 shedding of T-tropic virus. The differential effects
of FP on gp120 shedding of T- and M-tropic viruses
provide further evidence that FP binds to a site on HIV-1
envelope glycoprotein which influences gp120 shedding
from gp41. The results from shedding experiments reflect
a conformational difference between the T- and M-tropic
viruses in relation to gp120/41.
Previous reports have shown that the conformations of
the envelope glycoproteins of T- and M-tropic viruses are
different (De Jong et al., 1992; Ebenbichler et al., 1993;
Fouchier et al., 1992; Koito et al., 1994; Kozak et al., 1997;
Orloff et al., 1993). Conformational differences are also
manifested at viral entry through different coreceptor
usage as well as in inducing syncytium formation in
T-cell lines by laboratory-adapted T-tropic virus, but not
by M-tropic virus. Primary T- and M-tropic isolates also
show differential sensitivity to infection of cells express-
ing variable amounts of the primary receptor CD4. The
laboratory-adapted T-tropic virus demonstrates a re-
duced dependency on cellular CD4 than does the T-
tropic primary isolate for infection of cells (Kozak et al.,
1997).
The conformational changes in gp120 upon CD4 bind-
ing are sufficient to cause gp120 shedding from labora-
tory T-tropic virus. Primary M-tropic virus generally does
not shed gp120 readily in the presence of CD4 alone,
although CD4 binding still induces conformational
changes in gp120/41 (Sattentau et al., 1993; Stamatatos
et al., 1995; Sullivan et al., 1995). Since FP did not inhibit,
but rather enhanced, gp120 shedding of the M-tropic
virus ADA, it appears that a conformational change still
occurred in the gp120 shedding from M-tropic virus in the
presence of FP. The shedding results from M-tropic virus
suggest that FP inhibits M-tropic virus entry through a
different mechanism operating on gp120/41. The data of
our shedding assay not only reflected a conformational
difference between T- and M-tropic viruses, but also a
different fusion process between these viruses (Thali et
al., 1992; Ugolini et al., 1997; Wu et al., 1996).
Future studies are aimed at understanding the molec-
ular details of the interaction between FP and gp120/41
during the membrane fusion process. The study of this
novel compound may provide insight into the membrane
fusion process in viral entry as well as in syncytium
formation of M- and T-tropic viruses.
MATERIALS AND METHODS
Virus and cell
HIV-1IIIB/H9 was obtained from NIH AIDS Research
and Reference Reagent Program. The virus was filtered
and titrated before being used in the study. HIV-1 ADA is
a gift from Dr. Gabuzda. HIV-1 with an altered sensitivity
to FP was isolated by Fuji ImmunoPharmaceutical Corp.
and has FP induced point mutations in gp120 (Ono et al.,
1997). SIVmac239 and SIVmac251 are the gifts from Drs.
Desrosiers and Letvin.
The recombinant viruses containing either HXBc2 en-
velope or YU2 envelope were prepared as previously
described (Gottlinger et al., 1993; Terwilliger et al., 1989).
Briefly, HeLa cells were cotransfected by the calcium
phosphate method either with 15 mg pHXBH10DenvCAT
alone or with 15 mg pHXBH10DenvCAT and 3 mg pSVII-
Ienv or SV-A-MLV-Env to produce the recombinant viri-
ons. The recombinant viruses employed in the experi-
ments were HIV-1 with envelope glycoprotein of YU2 and
HXBc2 and a virus with SIVmac239 envelope glycopro-
teins that was generated with the same method.
PBMC were collected from the blood of HIV-1 anti-
body-negative healthy donors and separated with Ficoll–
Hypaque. The cells were stimulated with PHA and cul-
tured in RPMI 1640 medium for 48–72 h (Hollinger, 1994)
before being used in the study. The Cf2Th canine thymo-
cyte line was obtained from the American Type Culture
Collection and was propagated in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum.
Infection and transfection
A TCID50 of 2000 of each HIV-1 or SIV virions was used
to acutely infect 106 PBMC in each study. An equal
TABLE 1b
Targeted Steps in the HIV-1 Replication Cycle Examined with FP
HIV-1 replication step Inhibition by FP
Adsorption No
Entry Yes
RT activity No
Early mRNA expression No
HIV-1 genomic mRNA expression Not done
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number of reverse transcriptase units of the recombinant
viruses in the HeLa supernatants was used to infect
Cf2Th canine thymocytes, in the study of FP inhibiting
CD4/CXCR4 and CD4/CCR5 facilitated HIV-1 infection.
Compound
FP-21399 was provided by Fuji ImmunoPharmaceuti-
cal Corp. The compound was dissolved in PBS and
diluted to the appropriate concentrations in each assay.
The basic properties of the compound have been de-
scribed previously (Ono et al., 1997).
Time of addition experiment
FP was added to PBMC cultures following acute in-
fection with HIV-1IIIB. The cells and supernatants were
harvested at 68 h postinfection. The unbound viruses
were washed off with phosphate-buffered saline (PBS)
after HIV-1 was incubated with PBMC at 37°C for 120
min. FP was added to cultures at designated time points
and washed off after incubation with cells for 2 h. The
assay was carried out in duplicate in 24-well plates and
2 3 106 cells were used under each condition. The
culture was terminated at day 2.8 (postinfection 68 h).
Cell viability was examined with the MTT assay (Mos-
mann, 1983) in triplicate in 96-well plates.
Viral attachment assay
A TCID50 of 100 of HIV-1IIIB was incubated with 6 3 10
6
PBMC at 37°C for 30, 60, 120, and 300 min. Four micro-
molars of FP was added at the same time as virus to
cells. The cells were washed with PBS after the incuba-
tion and cell pellets were lysed by RIPA buffer (0.15 M
NaCl, 0.05 M Tris–Cl, pH 7.5, 1% Triton X-100, 0.1% SDS,
0.5% DOC). The antigen p24 in the cell lysate was de-
tected with HIV-1 p24 assay.
HIV-1 p24 assay
The HIV-1 p24 core profile ELISA kit (Dupont NEN,
Boston, MA) was used for detection of p24 production
after drug treatment. All procedures followed the manu-
facturer’s instructions for the kinetic assay.
HIV-1 LTR PCR
The PCR included the sense 59-CCTTGATCTGTG-
GATCTACC-39 and antisense 59-GCTTAATACTGACG-
CTCTCGCA-39 primers at a final concentration of 0.5 mM,
which amplify a full length 59 LTR of HIV-1. Taq poly-
merase and the reaction buffer were from Promega Corp.
(Madison, WI). A total of 0.5 mg of genomic DNA was
used per reaction. The samples were amplified through
30 cycles with the following parameters: denaturation at
94°C for 1 min, primer annealing at 55°C for 2 min, and
primer extension at 72°C for 2 min. The final cycle in-
cluded a 7-min extension at 72°C. b-Globin DNA, as a
control included in every PCR test, was amplified in
parallel with the test samples under the same conditions.
The primers were synthesized according to published
sequences (Saiki et al., 1988).
RNA PCR
Total cellular RNA was prepared with RNAzol B buffer
according to the manufacturer’s instructions (TEL-TEST,
Inc. Friendswood, TX). cDNA synthesis was done ac-
cording to a published method (Klotman et al., 1991). The
primers for HIV-1 early mRNA species were synthesized
according to published sequences (Klotman et al., 1991).
Gp120 shedding assay
The natural and sCD4-induced gp120 shedding exper-
iment was performed in cultures of COS-1 cells trans-
fected with envelope expressor plasmids as described
previously (Thali et al., 1992). FP-21399 was added 30
min before 20 mg/ml sCD4 was applied to the culture.
After incubation at 37°C for 1 h, the cultures were har-
vested, immunoprecipitated (Thali et al., 1992), and ex-
amined on 7.5% Tris–HCl polyacrylamide ready gel (Bio-
Rad, Hercules, CA).
Immunofluorescent staining assay
HIV-1IIIB acutely infected PBMC and drug-treated in-
fected PBMC were harvested at 40 and 120 min postin-
fection. TCID50 (2000) of virions was used to acutely
infect 106 PBMC. The cells were thoroughly washed with
1% bovine serum albumin (BSA)–PBS and directly
blocked with 2% donkey serum in 1% BSA–PBS without
fixing. The staining procedure followed per the protocol
of Transduction Laboratories (Lexington, KY). The pri-
mary antibody used for staining is a mouse mAb to
human HIV-1 gp120 (NEA-9201, Dupont NEN). This mAb
is sequence specific but not neutralizing. Texas red
(TRSC)-conjugated and affinity-purified anti-mouse IgG
(H 1 L) were obtained from Jackson ImmunoResearch
laboratories, Inc. (West Grove, PA). The stained samples
were mounted on a glass slide and sealed with a cov-
erslip. The slide was decontaminated and examined
under the fluorescent microscope within 2 h after the
staining.
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